From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit Feb 16 2026 In a significant step forward for mucosal immunity, Aptar Pharma has announced that its innovative nasal delivery systems are being utilized in CastleVax’s Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate. The trial is designed to evaluate the safety and immunogenicity of the vaccine, which aims to provide a more robust immune response at the site of infection (the respiratory tract) than

Tag-uri: Coronavirus